Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's mission is to develop transformative therapeutic products for large unmet clinical needs in procedure-based medicine. Its headquarters are located in New Hope, Pennsylvania, United States.

The company's flagship product candidates include Atrioventricular Interval Modulation (AVIM) Therapy, an investigational bioelectronic treatment designed to lower blood pressure, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a drug-device combination product for the treatment of atherosclerotic artery disease. Orchestra BioMed also has other product candidates in its pipeline, such as Cardiac Neuromodulation Therapy (CNT) for heart failure, and primarily operates through strategic collaborations with global medical device manufacturers like Medtronic and Terumo.

David P. Hochman serves as the Chairman, Chief Executive Officer, and Founder of Orchestra BioMed, with Darren R. Sherman as President, Chief Operating Officer, and Co-Founder, and Andrew Taylor as Chief Financial Officer. Recent notable developments include receiving a second FDA Breakthrough Device Designation for AVIM Therapy and securing strategic investments from partners such as Medtronic and Ligand. The company reported its Q1 2026 financial results and is targeting the completion of enrollment for its BACKBEAT Trial by the third quarter of 2026.